Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease

Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease Adv Ther (2017) 34:2007–2021 DOI 10.1007/s12325-017-0587-7 ORIGINAL RESEARCH Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease . . . Heather Strong Monica J. Mitchell Alana Goldstein-Leever . . Lisa Shook Punam Malik Lori E. Crosby Received: October 19, 2016 / Published online: July 17, 2017 Springer Healthcare Ltd. 2017 transplantation, the only curative treatment, is ABSTRACT available to less than 20% of patients because of a number of access barriers. Gene transfer ther- Introduction: Sickle cell disease (SCD) is a apy (GTT) has been shown to be curative in chronic genetic disease with high morbidity animal models and is approved for use in and early mortality; it affects nearly 100,000 humans for early-phase studies at a few centers. individuals in the USA. Bone marrow GTT would offer a more accessible treatment option available to all patients. It is important Punam Malik and Lori E. Crosby are co-senior authors. to understand patient perspectives on GTT to help ensure human clinical trial success. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/30E8 Methods: Two focus groups were conducted F060677D333B. with younger (18–30 years) and older (31 years and older) adults with SCD to obtain data on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease

Loading next page...
 
/lp/springer_journal/patient-perspectives-on-gene-transfer-therapy-for-sickle-cell-disease-YQi22UyjfI
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by Springer Healthcare Ltd.
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0587-7
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:2007–2021 DOI 10.1007/s12325-017-0587-7 ORIGINAL RESEARCH Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease . . . Heather Strong Monica J. Mitchell Alana Goldstein-Leever . . Lisa Shook Punam Malik Lori E. Crosby Received: October 19, 2016 / Published online: July 17, 2017 Springer Healthcare Ltd. 2017 transplantation, the only curative treatment, is ABSTRACT available to less than 20% of patients because of a number of access barriers. Gene transfer ther- Introduction: Sickle cell disease (SCD) is a apy (GTT) has been shown to be curative in chronic genetic disease with high morbidity animal models and is approved for use in and early mortality; it affects nearly 100,000 humans for early-phase studies at a few centers. individuals in the USA. Bone marrow GTT would offer a more accessible treatment option available to all patients. It is important Punam Malik and Lori E. Crosby are co-senior authors. to understand patient perspectives on GTT to help ensure human clinical trial success. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/30E8 Methods: Two focus groups were conducted F060677D333B. with younger (18–30 years) and older (31 years and older) adults with SCD to obtain data on

Journal

Advances in TherapySpringer Journals

Published: Jul 17, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off